Qpex Biopharma

About Qpex Biopharma

Qpex Biopharma develops therapeutic agents that target antibiotic-resistant infections and viral diseases through advanced drug discovery techniques. The company focuses on providing effective treatments to combat the growing threat of infectious pathogens worldwide.

```xml <problem> The increasing prevalence of antimicrobial resistance (AMR) poses a significant threat to global public health, as many infections are becoming difficult or impossible to treat with existing antibiotics. This is often due to specific pathogens and resistance mechanisms that afflict smaller patient populations, making the development of effective treatments challenging. The lack of new, targeted therapeutics leaves clinicians with limited options for combating drug-resistant bacteria. </problem> <solution> Qpex Biopharma, a Shionogi Group Company, focuses on developing novel anti-infective therapies to combat multi-drug resistance by understanding and overcoming resistance mechanisms. The company employs advanced drug discovery techniques to improve existing proven classes of drugs and identify new chemical classes that can overcome drug resistance. Qpex Biopharma aims to reverse drug resistance mechanisms and restore antibiotic potency against drug-resistant bacteria, ultimately providing targeted therapeutics for smaller patient populations. </solution> <features> - Focus on understanding and overcoming drug resistance mechanisms in infectious diseases - Development of novel products and strategies to combat multi-drug resistance - Improvement of existing antibiotic classes to enhance their effectiveness - Discovery of new chemical classes of drugs that can overcome resistance - Reversal of drug resistance mechanisms to restore antibiotic potency - Partnerships to accelerate the development and impact of products </features> <target_audience> The primary target audience includes patients suffering from infections caused by drug-resistant pathogens, as well as healthcare providers seeking effective treatment options for these infections. </target_audience> ```

What does Qpex Biopharma do?

Qpex Biopharma develops therapeutic agents that target antibiotic-resistant infections and viral diseases through advanced drug discovery techniques. The company focuses on providing effective treatments to combat the growing threat of infectious pathogens worldwide.

Where is Qpex Biopharma located?

Qpex Biopharma is based in San Diego, United States.

When was Qpex Biopharma founded?

Qpex Biopharma was founded in 2018.

How much funding has Qpex Biopharma raised?

Qpex Biopharma has raised 10000000.

Location
San Diego, United States
Founded
2018
Funding
10000000
Employees
31 employees
Major Investors
Biomedical Advanced Research and Development Authority (BARDA)

Find Investable Startups and Competitors

Search thousands of startups using natural language

Qpex Biopharma

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Qpex Biopharma develops therapeutic agents that target antibiotic-resistant infections and viral diseases through advanced drug discovery techniques. The company focuses on providing effective treatments to combat the growing threat of infectious pathogens worldwide.

qpexbio.com1K+
cb
Crunchbase
Founded 2018San Diego, United States

Funding

$

Estimated Funding

$10M+

Major Investors

Biomedical Advanced Research and Development Authority (BARDA)

Team (30+)

No team information available.

Company Description

Problem

The increasing prevalence of antimicrobial resistance (AMR) poses a significant threat to global public health, as many infections are becoming difficult or impossible to treat with existing antibiotics. This is often due to specific pathogens and resistance mechanisms that afflict smaller patient populations, making the development of effective treatments challenging. The lack of new, targeted therapeutics leaves clinicians with limited options for combating drug-resistant bacteria.

Solution

Qpex Biopharma, a Shionogi Group Company, focuses on developing novel anti-infective therapies to combat multi-drug resistance by understanding and overcoming resistance mechanisms. The company employs advanced drug discovery techniques to improve existing proven classes of drugs and identify new chemical classes that can overcome drug resistance. Qpex Biopharma aims to reverse drug resistance mechanisms and restore antibiotic potency against drug-resistant bacteria, ultimately providing targeted therapeutics for smaller patient populations.

Features

Focus on understanding and overcoming drug resistance mechanisms in infectious diseases

Development of novel products and strategies to combat multi-drug resistance

Improvement of existing antibiotic classes to enhance their effectiveness

Discovery of new chemical classes of drugs that can overcome resistance

Reversal of drug resistance mechanisms to restore antibiotic potency

Partnerships to accelerate the development and impact of products

Target Audience

The primary target audience includes patients suffering from infections caused by drug-resistant pathogens, as well as healthcare providers seeking effective treatment options for these infections.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.